Clinuvel Pharmaceuticals Ltd
OTC:CLVLY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Clinuvel Pharmaceuticals Ltd
OTC:CLVLY
|
AU |
|
C
|
Compagnia Dei Caraibi SpA
MIL:1TIME
|
IT |
|
Cryoport Inc
NASDAQ:CYRX
|
US |
|
V
|
Vulcan Materials Co
F:VMC
|
US |
|
ATS Automation Tooling Systems Inc
TSX:ATA
|
CA |
|
I
|
Intel Corp
XHAM:INL
|
US |
|
Lufax Holding Ltd
F:6V3
|
CN |
|
A
|
Allstate Corp
XHAM:ALS
|
US |
|
Transcat Inc
NASDAQ:TRNS
|
US |
Wall St Price Targets
CLVLY Price Targets Summary
Clinuvel Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for CLVLY is 16.21 USD with a low forecast of 7.41 USD and a high forecast of 33.01 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is CLVLY's stock price target?
Price Target
16.21
USD
According to Wall Street analysts, the average 1-year price target for CLVLY is 16.21 USD with a low forecast of 7.41 USD and a high forecast of 33.01 USD.
What is the Revenue forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 39%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
8%
The compound annual growth rate for Gross Profit over the next 8 years is 8%.
What is the Operating Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
9%
The compound annual growth rate for Operating Income over the next 8 years is 9%.
What is the Pre-Tax Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
12%
The compound annual growth rate for Pre-Tax Income over the next 4 years is 12%.
What is the Net Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
11%
The compound annual growth rate for Net Income over the next 8 years is 11%.
